60
Participants
Start Date
April 1, 2019
Primary Completion Date
December 15, 2027
Study Completion Date
December 15, 2027
Nonacog beta pegol
Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
AKH - Klin. Abt. f. Haematologie u. Haemostaseologie, Vienna
Cliniques universitaires Saint-Luc - Service Hématologie, Brussels
Skejby Blodsygdomme, blødercentret, Aarhus N
Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain, Berlin
"Laiko General Hospital of Athens", Athens
Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie, Bonn
Univ of Alberta Hospital Res, Edmonton
CancerCare Manitoba, Winnipeg
Health Science Centre, St. John's
Hamilton Health Sciences Corp, Ontario, Hamilton
Hamltn Hth Sci/McMstr Child Hosp, Hamilton
The Hospital for Sick Children, Toronto
KBC Zagreb, Rebro, Hemofilija centar, Zagreb
FN Brno odd. hematologie, Brno
Fakultni nemocnice Plzen - Lochotin, Pilsen
Helsinki University Central Hospital/Coagulation Disorder Un, Helsinki
"Laiko General Hospital of Athens", Athens
Aghia Sophia Childrens' Hospital, Athens
Klinisk forskningspost, Oslo
Hospital São José, Lisbon
Unidade Local de Saúde São José EPE- Hospital D. Estefânia, Lisbon
Arthur Bloom Haemophilia Centre, Cardiff
Royal Hallamshire Hospital, Sheffield
Lead Sponsor
Novo Nordisk A/S
INDUSTRY